A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo

Molecular Cancer Therapeutics

Volumn 1, Issue 7, 2002, Pages 451-459

  DeFeo Jones, Deborah ^a   Brady, Stephen F ^b   Feng, Dong Mei ^b   Wong, Bradly K ^c   Bolyar, Trina ^a   Haskell, Kathleen ^a   Kiefer, David M ^a   Leander, Karen ^a   McAvoy, Elizabeth ^a   Lumma, Patricia ^b   Pawluczyk, Joseph M ^b   Wai, Jenny ^b   Motzel, Sherri L ^d   Keenan, Kevin ^e   Van Zwieten, Matthew ^e   Lin, Jiunn H ^c   Garsky, Victor M ^b   Freidinger, Roger ^b   Oliff, Allen ^f   Jones, Raymond E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Medicinal Chemistry   (United States)

^c Drug Metabolism Department   (United States)

^d Laboratory Animal Resources   (United States)

^e Safety   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; PRODRUG; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL CULTURE; CHEMICAL MODEL; DOG; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOGS; DOXORUBICIN; HUMANS; MALE; MICE; MICE, NUDE; MODELS, CHEMICAL; NEOPLASM TRANSPLANTATION; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 18844470751     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. DeFeo-Jones, D., Garsky, V. M., Wong, B. K., Feng, D-M. Bolyar, T., Haskell, K., Kiefer, D. M., Leander, K., McAvoy, E., Lumma, P., Wai, J., Senderak, E. T., Motzel, S. L., Keenan, K., Van Zwieten, M., Lin, J. H., Freidinger, R., Huff, J., Oliff, A., and Jones, R. E. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med., 6: 1248-1252, 2000.
2. Denmeade, S. R., Nagy, A., Gao, J., Lilja, H., Schally, A. V., and Isaacs, J. T. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res., 58: 2537-2540, 1998. (Pubitemid 28275422)
3. Khan, S. R., and Denmeade, S. R. In vivo activity of a psa-activated doxorubicin prodrug against psa-producing human prostate cancer xenografts. Prostate, 45: 80-83, 2000.
4. Diamandis, E., Yu, H., and Sutherland, D. J. A. Detection of prostatespecific antigen immunoreactivity in breast tumors. Breast Cancer Res. Treat., 32: 301-310, 1994. (Pubitemid 24351377)
5. Yu, H., Diamandis, E., and Sutherland, D. J. A. Immunoreactive pros-tate- specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin. Biochem., 27: 75-79, 1994. (Pubitemid 24146156)
6. Levesque, M., Yu, H., D'Costa. M., and Diamandis, E. Prostate-specific antigen expression by various tumors. J. Clin. Lab. Anal., 9: 123-128, 1995.
7. Malm, J., Hellman, J., Hogg, P., and Lilja, H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate, 45: 132-139, 2000.
8. Christensson, A., Laurell, C., and Lilja, H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem., 194: 755-763, 1990.
9. Leinonen, H. J., Zhang, W., and Stenman, U. Complex formation between PSA isoenzymes and protease inhibitors. J. Urol., 155: 1099-1103, 1996. (Pubitemid 26052723)
10. Otto, A., Bar, I., and Birkenmeir, B. Prostate-specific antigen forms complexes with human α2-macroglobulin receptor/ldl receptor-related protein. J. Urol., 159: 297-303, 1998.
11. Lilja, H. A kalikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Investig., 76: 1899-1903, 1985. (Pubitemid 16196061)
12. Lilja, H., Oldbring, J., Ramevik, G., and Laurell, C-B. Seminal vesicle secreted proteins and their reactions during gelation and liquefication of human semen. J. Clin. Investig., 80: 281-285, 1987.
13. Garsky, V. M., Lumma, P. K., Feng, D-M. Wai, J., Ramjit, H. G., Sardana, M. K., Oliff, A. O., Jones, R. E., DeFeo-Jones, D., and Freidinger, R. M. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J. Med. Chem., 44: 4216-4224, 2001. (Pubitemid 33095328)
14. O'Connor, P. M., Jackman, J., Bae, I., Myers, T. G., Fan, S., Mutoh, M., Scudiero, D. A., Monks, A., Sausville, E. A., Weinstein, J. N., Friend, S., Fornace, A. J., and Kohn, K. V. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with growth-inhibitory potency of 123 anticancer agents. Cancer Res., 57: 4285-4300, 1997. (Pubitemid 27413438)
15. Stadtmauer, E. A., O'Neill, A. Goldstein, L. J., Crilley, P. A., Mangan, K. F., Ingle, J. N., Brodsly, I., Martino, S., Lazarus, H. M., Erban, J. K., Sickles, C., and Glick, J. H. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologuous hematopoietic stem-cell transplantation for metastatic breast cancer. N. Eng. J. Med., 342: 1069-1076, 2000. (Pubitemid 30207689)
16. Physicans Desk Reference, Medical Economics Company, Inc., 2001.
17. Carter, S. K. Principles of cancer chemotherapy. In: G. H. Theilen and B. R. Madewell (eds.), Veterinary Cancer Medicine, pp. 167-182. Philadelphia: Lea & Febiger, 1987.
18. Wong, B. K., DeFeo-Jones, D., Jones, R. E., Garsky, V. M., Feng, D-M. Oliff, A., Chiba, M., Ellis, J. D., and Lin, J. H. PSA-specific and non-psa-specific conversion of a psa-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab. Dispos., 29: 313-318, 2001. (Pubitemid 32179533)
19. DiPaola, R. S., Rinehart, J., Neminaitis, J., Ciardella, M., Goodin, S., Adams, N., Williams, A., Schwartz, M., Winchell, G., Wichersham, M., Deutsch, P., Dula, D., Gleason, D., and Yao, S. A phase I and II trial of a psa activated peptide-doxorubicin conjugate, with and without prednisone, in patients with hormone refractory prostate cancer. Am. Soc. Clin. Oncol., Abs 727, 2001.